PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...
Obesity alters bone health not only through increased body weight but also by reshaping the bone marrow environment.
Insights into the workings of an immune cell surface receptor, called PD-1, reveal how treatments that restrict its action can potentially be strengthened to improve their anticancer effect, a new ...
Treatment with programmed cell death 1/programmed cell death ligand 1 inhibitors for Kaposi sarcoma: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Non-metastatic gastric cancer (GC) in patients aged 80 years or older: Immediate and long-term outcomes of combined treatment. Individual patient data (IPD) pooled analysis on the optimal therapeutic ...
When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...
Ivonescimab is a next-generation bispecific antibody that simultaneously targets programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), two key molecules in the tumour ...
Mouse analog of MICVO (maMICVO) monotherapy produced dose-dependent inhibition of tumor growth in a syngeneic preclinical model of HNSCCmaMICVO ...
Most scientists agree that age-related immune dysfunction—in one form or another—factors strongly into Alzheimer’s and other neurodegenerative diseases. The mechanisms involved are far less settled, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results